Video
Dr. Katie S. Murray looks back on bladder cancer research from AUA 2023
Author(s):
Katie S. Murray, DO, recaps several presentations on bladder cancer from the 2023 American Urological Association Annual Meeting in Chicago, Illinois.
In this video, Katie S. Murray, DO, recaps several presentations on bladder cancer from the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Murray is a member of the faculty in the in the department of urology at NYU Grossman School of Medicine and chief of the Urology Service at Bellevue Hospital Center in New York, New York.
The following abstracts are discussed:
1. LBA02-03 (Daneshmand et al): First results from SunRISE-1 in patients with BCG unresponsive high-risk non-muscle-invasive bladder cancer receiving TAR-200 in combination with cetrelimab, TAR-200, or cetrelimab alone
2. LBA03-08 (Singer et al): Pembrolizumab (pembro) for patients (pts) with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Efficacy and evaluation of subsequent cystectomy from cohort B of the phase 2 KEYNOTE-057 study
3. MP47-04 (Dhanji et al): Hypertension is associated with worsened survival outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma: analysis of the ROBUUST registry
